John Evans, Beam Therapeutics CEO

Beam dos­es first pa­tient with base-edit­ed cell ther­a­py

Beam Ther­a­peu­tics an­nounced Tues­day that it dosed its first pa­tient with its base-edit­ed CAR-T treat­ment last month.

BEAM-201 is an “off-the-shelf” cell ther­a­py for pa­tients with T-cell acute lym­phoblas­tic leukemia (T-ALL) or T-cell lym­phoblas­tic lym­phoma (T-LL) that has come back af­ter pri­or treat­ment. Beam CEO John Evans said in a press state­ment that Beam’s pa­tient was the first in the US to re­ceive a base edit­ing ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.